Literature DB >> 16364641

The existence of a second allosteric site on the M1 muscarinic acetylcholine receptor and its implications for drug design.

L Michel Espinoza-Fonseca1, José G Trujillo-Ferrara.   

Abstract

Fully flexible docking of KT5720, an allosteric modulator of the muscarinic receptors, was performed on a dynamic model of the M(1) muscarinic acetylcholine receptor. The results confirmed the existence of a second allosteric site, located on the intracellular face of the receptor. These results would be beneficial for the design of modulators of this receptor to be used as an effective alternative against the Alzheimer's disease.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16364641     DOI： 10.1016/j.bmcl.2005.11.097

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  9 in total

1.  Long-term wash-resistant effects of brief interaction of xanomeline at the M1 muscarinic receptor.

Authors:  Kayla C De Lorme; Krista L Sikorski; Marianne K O Grant; Esam E El-Fakahany
Journal:  Neurosci Lett       Date:  2006-10-18       Impact factor: 3.046

Review 2.  Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders.

Authors:  Liyun Wang; Bronwen Martin; Randall Brenneman; Louis M Luttrell; Stuart Maudsley
Journal:  J Pharmacol Exp Ther       Date:  2009-08-10       Impact factor: 4.030

3.  Toward prediction of functional protein pockets using blind docking and pocket search algorithms.

Authors:  Csaba Hetényi; David van der Spoel
Journal:  Protein Sci       Date:  2011-03-30       Impact factor: 6.725

Review 4.  Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.

Authors:  Briana J Davie; Arthur Christopoulos; Peter J Scammells
Journal:  ACS Chem Neurosci       Date:  2013-05-23       Impact factor: 4.418

5.  Quinoline derivatives: candidate drugs for a class B G-protein coupled receptor, the calcitonin gene-related peptide receptor, a cause of migraines.

Authors:  Hira Iftikhar; Iqra Ahmad; Siew H Gan; Munvar M Shaik; Naveed Iftikhar; Muhammad S Nawaz; Nigel H Greig; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

Review 6.  Muscarinic acetylcholine receptors: novel opportunities for drug development.

Authors:  Andrew C Kruse; Brian K Kobilka; Dinesh Gautam; Patrick M Sexton; Arthur Christopoulos; Jürgen Wess
Journal:  Nat Rev Drug Discov       Date:  2014-06-06       Impact factor: 84.694

7.  Exploration of the valproic acid binding site on histone deacetylase 8 using docking and molecular dynamic simulations.

Authors:  Jorge Antonio Bermúdez-Lugo; Oscar Perez-Gonzalez; Martha Cecilia Rosales-Hernández; Ian Ilizaliturri-Flores; José Trujillo-Ferrara; Jose Correa-Basurto
Journal:  J Mol Model       Date:  2011-10-04       Impact factor: 1.810

Review 8.  Use of allosteric targets in the discovery of safer drugs.

Authors:  Ashok Kumar Grover
Journal:  Med Princ Pract       Date:  2013-05-23       Impact factor: 1.927

9.  Probing the binding site of novel selective positive allosteric modulators at the M1 muscarinic acetylcholine receptor.

Authors:  Elham Khajehali; Celine Valant; Manuela Jörg; Andrew B Tobin; P Jeffrey Conn; Craig W Lindsley; Patrick M Sexton; Peter J Scammells; Arthur Christopoulos
Journal:  Biochem Pharmacol       Date:  2018-05-17       Impact factor: 5.858
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.